(PRA) ProAssurance - Overview
Stock: Professional Liability, Medical Liability, Workers Compensation, Reinsurance
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 4.74% |
| Relative Tail Risk | -14.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.04 |
| Alpha | 57.41 |
| Character TTM | |
|---|---|
| Beta | 0.034 |
| Beta Downside | 0.353 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.09% |
| CAGR/Max DD | 0.18 |
Description: PRA ProAssurance January 18, 2026
ProAssurance Corporation (NYSE:PRA) operates three primary segments-Specialty Property & Casualty, Workers’ Compensation Insurance, and Segregated Portfolio Cell (SPC) Reinsurance-offering professional-liability coverage for healthcare providers, attorneys, and medical-technology firms, as well as customized alternative-risk solutions such as assumed reinsurance and loss-portfolio transfers. Its Workers’ Compensation line includes guaranteed-cost, dividend-eligible, retrospectively-rated, and deductible policies, supplemented by fronting, claims-administration, and SPC-management services delivered through independent brokers and an internal sales team. The firm, founded in 1976, is headquartered in Birmingham, Alabama.
Key recent metrics (Q4 2023) show PRA generating $1.08 billion in total revenue, with a combined ratio of roughly 94% in its Specialty P&C segment-indicating underwriting profitability-but a higher 98% ratio in Workers’ Compensation, reflecting pricing pressure from rising labor costs. The SPC Reinsurance business contributed $210 million of net income, driven by increasing demand for captive-cell structures amid heightened healthcare liability exposure. Sector-wide, the U.S. P&C market is sensitive to interest-rate shifts (affecting investment yield) and inflation-linked claim severity, both of which remain material risk factors for PRA’s earnings outlook.
For a deeper, data-driven look at PRA’s valuation and risk profile, you might explore the analyst tools available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: 33.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 0.05 > 1.0 |
| NWC/Revenue: 53.32% < 20% (prev 413.7%; Δ -360.3% < -1%) |
| CFO/TA -0.00 > 3% & CFO -12.7m > Net Income 33.7m |
| Net Debt (382.4m) to EBITDA (79.9m): 4.78 < 3 |
| Current Ratio: 39.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.8m) vs 12m ago 0.93% < -2% |
| Gross Margin: 22.42% > 18% (prev 0.22%; Δ 2220 % > 0.5%) |
| Asset Turnover: 19.48% > 50% (prev 19.88%; Δ -0.40% > 0%) |
| Interest Coverage Ratio: 3.11 > 6 (EBITDA TTM 79.9m / Interest Expense TTM 21.0m) |
Altman Z'' 1.96
| A: 0.11 (Total Current Assets 601.5m - Total Current Liabilities 15.3m) / Total Assets 5.55b |
| B: 0.26 (Retained Earnings 1.45b / Total Assets 5.55b) |
| C: 0.01 (EBIT TTM 65.2m / Avg Total Assets 5.64b) |
| D: 0.32 (Book Value of Equity 1.36b / Total Liabilities 4.25b) |
| Altman-Z'' Score: 1.96 = BBB |
Beneish M -0.65
| DSRI: 0.90 (Receivables 637.1m/732.8m, Revenue 1.10b/1.14b) |
| GMI: 0.99 (GM 22.42% / 22.20%) |
| AQI: 5.18 (AQ_t 0.89 / AQ_t-1 0.17) |
| SGI: 0.96 (Revenue 1.10b / 1.14b) |
| TATA: 0.01 (NI 33.7m - CFO -12.7m) / TA 5.55b) |
| Beneish M-Score: -0.65 (Cap -4..+1) = D |
What is the price of PRA shares?
Over the past week, the price has changed by +0.54%, over one month by +1.33%, over three months by +1.50% and over the past year by +59.99%.
Is PRA a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PRA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25 | 2.7% |
| Analysts Target Price | 25 | 2.7% |
| ValueRay Target Price | 26.6 | 9.1% |
PRA Fundamental Data Overview February 03, 2026
P/E Forward = 16.8634
P/S = 1.1114
P/B = 0.9555
P/EG = 1.02
Revenue TTM = 1.10b USD
EBIT TTM = 65.2m USD
EBITDA TTM = 79.9m USD
Long Term Debt = 296.5m USD (from longTermDebt, last quarter)
Short Term Debt = 125.0m USD (from shortTermDebt, last quarter)
Debt = 436.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 382.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.63b USD (1.25b + Debt 436.8m - CCE 54.5m)
Interest Coverage Ratio = 3.11 (Ebit TTM 65.2m / Interest Expense TTM 21.0m)
EV/FCF = -89.28x (Enterprise Value 1.63b / FCF TTM -18.2m)
FCF Yield = -1.12% (FCF TTM -18.2m / Enterprise Value 1.63b)
FCF Margin = -1.66% (FCF TTM -18.2m / Revenue TTM 1.10b)
Net Margin = 3.07% (Net Income TTM 33.7m / Revenue TTM 1.10b)
Gross Margin = 22.42% ((Revenue TTM 1.10b - Cost of Revenue TTM 852.8m) / Revenue TTM)
Gross Margin QoQ = 19.66% (prev 29.56%)
Tobins Q-Ratio = 0.29 (Enterprise Value 1.63b / Total Assets 5.55b)
Interest Expense / Debt = 1.20% (Interest Expense 5.24m / Debt 436.8m)
Taxrate = 16.38% (10.3m / 63.1m)
NOPAT = 54.5m (EBIT 65.2m * (1 - 16.38%))
Current Ratio = 39.26 (Total Current Assets 601.5m / Total Current Liabilities 15.3m)
Debt / Equity = 0.33 (Debt 436.8m / totalStockholderEquity, last quarter 1.30b)
Debt / EBITDA = 4.78 (Net Debt 382.4m / EBITDA 79.9m)
Debt / FCF = -20.98 (negative FCF - burning cash) (Net Debt 382.4m / FCF TTM -18.2m)
Total Stockholder Equity = 1.25b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.60% (Net Income 33.7m / Total Assets 5.55b)
RoE = 2.69% (Net Income TTM 33.7m / Total Stockholder Equity 1.25b)
RoCE = 4.20% (EBIT 65.2m / Capital Employed (Equity 1.25b + L.T.Debt 296.5m))
RoIC = 3.25% (NOPAT 54.5m / Invested Capital 1.68b)
WACC = 4.73% (E(1.25b)/V(1.68b) * Re(6.04%) + D(436.8m)/V(1.68b) * Rd(1.20%) * (1-Tc(0.16)))
Discount Rate = 6.04% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.59%
Fair Price DCF = unknown (Cash Flow -18.2m)
EPS Correlation: 30.20 | EPS CAGR: -15.14% | SUE: -1.84 | # QB: 0
Revenue Correlation: -11.17 | Revenue CAGR: -2.14% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.21 | Chg30d=+0.010 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=1.07 | Chg30d=+0.055 | Revisions Net=+1 | Growth EPS=+1.4% | Growth Revenue=-5.9%